1. Home
  2. DRUG vs PUBM Comparison

DRUG vs PUBM Comparison

Compare DRUG & PUBM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DRUG
  • PUBM
  • Stock Information
  • Founded
  • DRUG 2019
  • PUBM 2006
  • Country
  • DRUG United States
  • PUBM United States
  • Employees
  • DRUG N/A
  • PUBM N/A
  • Industry
  • DRUG Pharmaceuticals and Biotechnology
  • PUBM Computer Software: Prepackaged Software
  • Sector
  • DRUG Health Care
  • PUBM Technology
  • Exchange
  • DRUG Nasdaq
  • PUBM Nasdaq
  • Market Cap
  • DRUG 484.7M
  • PUBM 406.5M
  • IPO Year
  • DRUG N/A
  • PUBM 2020
  • Fundamental
  • Price
  • DRUG $69.38
  • PUBM $8.48
  • Analyst Decision
  • DRUG Strong Buy
  • PUBM Buy
  • Analyst Count
  • DRUG 9
  • PUBM 11
  • Target Price
  • DRUG $81.67
  • PUBM $18.05
  • AVG Volume (30 Days)
  • DRUG 108.7K
  • PUBM 599.8K
  • Earning Date
  • DRUG 08-11-2025
  • PUBM 11-10-2025
  • Dividend Yield
  • DRUG N/A
  • PUBM N/A
  • EPS Growth
  • DRUG N/A
  • PUBM N/A
  • EPS
  • DRUG N/A
  • PUBM N/A
  • Revenue
  • DRUG N/A
  • PUBM $292,208,000.00
  • Revenue This Year
  • DRUG N/A
  • PUBM N/A
  • Revenue Next Year
  • DRUG N/A
  • PUBM $1.40
  • P/E Ratio
  • DRUG N/A
  • PUBM N/A
  • Revenue Growth
  • DRUG N/A
  • PUBM 3.53
  • 52 Week Low
  • DRUG $23.18
  • PUBM $7.01
  • 52 Week High
  • DRUG $70.23
  • PUBM $17.74
  • Technical
  • Relative Strength Index (RSI)
  • DRUG 68.34
  • PUBM 51.26
  • Support Level
  • DRUG $62.21
  • PUBM $7.88
  • Resistance Level
  • DRUG $70.23
  • PUBM $8.37
  • Average True Range (ATR)
  • DRUG 6.00
  • PUBM 0.36
  • MACD
  • DRUG 0.52
  • PUBM 0.03
  • Stochastic Oscillator
  • DRUG 96.01
  • PUBM 46.66

About DRUG Bright Minds Biosciences Inc.

Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.

About PUBM PubMatic Inc.

PubMatic Inc is a supply-side platform provider in the digital advertising technology market. These platforms help publishers, which supply digital ad inventory, manage their inventory, selling a high percentage of their inventory (increase the ad fill rate) and maximizing revenue per ad sold (optimize yield). The company generates revenue mainly by taking a piece of the ad sales that it enables. Buyers on the platform include intermediary buyers, such as demand-side platforms, or advertisers and ad agencies directly. Geographically, the company generates the majority of its revenue from the United States, followed by EMEA and APAC.

Share on Social Networks: